Hua Hai Pharmaceutical: Obtained the Drug Registration Certificate for Malic Acid Telfilamine Tablets.

Hua Hai Pharmaceutical announced that it has recently received the "Drug Registration Certificate" for the malic acid mebutin tablets issued by the National Medical Products Administration, with the approval number being National Drug Approval H20263372. This drug is used to improve symptoms of gastrointestinal motility disorder and irritable bowel syndrome, with an estimated domestic market sales amount of approximately 340 million yuan in 2025. As of now, the company has invested about 10.1 million yuan in the research and development of this drug. The approved product is equivalent to passing consistency assessment, which will enrich the product line and enhance competitiveness, but production and sales are easily influenced by factors such as policies and market conditions.